
Mouse research points to a stress-hormone pathway that may slow gut movement. Learn what the findings mean for everyday digestive-health choices.

On Oct. 21, 2026, ASBMB reported that increased stress-hormone signaling reduced activity in a gut nerve pathway and slowed intestinal movement in mice. Its article described research published in the Journal of Biological Chemistry that focused on the signaling molecule BDNF and its receptor TrkB.
The starting point in ASBMB's account was the established role of the enteric nervous system, or ENS. This network of nerves in the gut helps coordinate gastrointestinal motility, meaning movement through the digestive tract. The study therefore examined a system already recognized as central to how the gut moves.
Srinivas N. Puttapaka said this role made the ENS a natural focus for investigating stress-related changes in gastrointestinal movement. The question was not whether the gut has its own nerve network. It was how stress-related hormonal signals might affect the activity of that network.
That distinction separates a broad biological understanding from a specific molecular explanation. Knowing which system coordinates movement gives researchers a place to look. Identifying a signaling molecule and receptor offers a more focused way to investigate how movement changes.
It also helps define the outcome under discussion. Motility refers to movement, not to every aspect of digestive wellbeing. Reading the findings as a report about a particular gut function is more precise than describing the experiment as a general improvement in “gut health.”
According to ASBMB, the study was co-led by Jared Slosberg of Johns Hopkins School of Medicine and Srinivas N. Puttapaka of Harvard Medical School. Their work focused on a pathway involving stress hormones and BDNF-TrkB signaling in the gut.
The contribution was a proposed sequence connecting a hormonal signal with a change in gut nerve signaling and a change in movement. That gives the stress-motility question a molecular focus: what happens when the signal received by these nerves is reduced?
BDNF stands for brain-derived neurotrophic factor. In this research, it is the signaling molecule of interest. TrkB stands for tropomyosin receptor kinase B and is the receptor involved in that signaling pathway. A receptor is the receiving part of a biological signaling system.
A useful way to read the terminology is to keep the molecule and receptor separate. The report describes less BDNF expression under increased glucocorticoid signaling. The later agonist experiment acts on TrkB. Those are different points in the same signaling pathway.
The stress-hormone part of the experiment involved glucocorticoid signaling. ASBMB reports that increased signaling of this kind was linked to a sequence of changes in the mouse models:
These are connected parts of the proposed mechanism rather than interchangeable findings. Reduced BDNF expression concerns the signaling molecule. Suppressed BDNF-TrkB activity concerns the pathway. Slower motility is the functional outcome, meaning the change in what the gut was doing.
This is why the pathway matters to the report. It places a specific signaling step between the hormonal condition being studied and the movement outcome the researchers observed. The explanation is more detailed than a simple statement that stress and digestion are related.
The investigators also tested an agonist, a substance that activates a receptor. In the experiments described by ASBMB, activating TrkB improved gut motility in mice with stress-associated constipation.
Puttapaka described that result as encouraging functional evidence that BDNF-TrkB signaling may regulate stress-associated gastrointestinal dysmotility. Dysmotility means altered or impaired movement. Here the researchers were looking at whether changing pathway activity also changed the movement problem.
As an interpretation of the experiment, this is the most informative step: the investigators did more than report reduced signaling alongside slower movement. They changed the activity of the receptor and observed an improvement in function.
In this sense, the experiment adds detail to the gut-brain discussion. The researchers did not use “stress” as the endpoint of their explanation. They followed a particular hormone-related signal into a local nerve-signaling pathway and examined movement. For readers, the useful shift is from a broad label to a testable biological question.
For broader background, DigestGenius's explanation of how the gut receives and processes signals provides an introduction to digestive sensing. The present report concerns a specific hormonal and nerve-signaling question within that wider subject.
No. ASBMB's separate article, “How the gut senses acidity to stay healthy,” concerns intestinal acidity sensing and the protein OTOP2. Its “How stress hormones slow gut motility” report concerns the stress-related pathway discussed here.
These stories should stay separate. OTOP2 belongs to the acidity-sensing account. The BDNF-TrkB findings belong to the stress-motility account. Combining their headlines would give the impression that the acidity study established the stress pathway when the supplied reports describe different research.
The key boundary is the experimental model. ASBMB describes mouse experiments and does not report a human treatment trial. The TrkB-agonist result therefore does not establish that this approach is effective or safe for people with stress-related constipation.
The account also leaves important details unreported. It provides no sample sizes, so readers cannot assess how many animals supported the comparisons. It gives no effect sizes or exact motility measurements, making it difficult to judge the size of the reported improvement. Those are limits of the information in the ASBMB report, not evidence that the underlying study omitted those measurements.
ASBMB reports a significant improvement in constipation or motility. That wording does not supply the missing measurements. A reported improvement and a clearly described magnitude of benefit are different pieces of information when judging the practical importance of an experiment.
No dose information is provided either. More broadly, the report supplies no dietary, supplement or lifestyle protocol. It supports investigation of a biological target rather than a consumer treatment recommendation.
Another boundary concerns personal interpretation. The study does not establish that this pathway explains any individual's recurring digestive symptoms. A plausible mechanism in the reported model is not a way to identify the cause of a person's constipation.
Together these constraints define the current evidence: an experimental pathway with a reported functional effect. They leave the clinical questions open, including whether acting on this pathway would produce a useful benefit in people.
Puttapaka outlined several next questions in the ASBMB report. The researchers plan to investigate which populations of enteric neurons depend most on BDNF-TrkB signaling. They also want to examine how chronic stress affects those neurons over time and whether similar molecular changes occur in other gastrointestinal disorders.
Those questions move the work toward greater precision. They ask about location, duration and scope. Identifying the relevant enteric nerve populations would clarify where the pathway matters most within the ENS. Studying chronic stress over time would address what happens to those neurons across a longer period.
Asking about other gastrointestinal disorders addresses a different issue: how widely the proposed mechanism might apply. That is a research question in its own right, separate from whether activating TrkB improved movement in the reported experiments.
For daily choices, the sensible response is to keep the experimental target separate from the dinner plate. Food decisions should rest on relevant nutrition evidence and individual needs, not on the appeal of a molecular explanation. DigestGenius's food and fiber learning resources offer a separate starting point for understanding everyday nutrition questions.
Likewise, decisions about recurring constipation belong with a qualified healthcare professional rather than a mechanism-focused headline. The useful editorial takeaway is a more concrete understanding of one possible stress-gut connection, not a reason to redesign a diet around BDNF or TrkB.
Deciding whether a stress-pathway finding should change an everyday routine is where DigestGenius adds educational context. Its educational platform uses free articles and detailed resources to address confusion about stress and digestion, helping adults interpret gut-brain research in plain language and distinguish an experimental mechanism from evidence that supports established guidance.
DigestGenius publishes research-led guidance on digestion, the gut microbiome, fiber, probiotics, gut-brain signaling, inflammation and everyday digestive wellbeing.



Explore clear, research-led guidance on digestion, the microbiome, food, fiber, probiotics and the gut-brain connection.
read the blog